

May 16, 2012
AnGes MG, Inc.

Collaboration with Morishita Jintan regarding New Formulation Development for Oral Vaccines
using Seamless Capsule Technology

AnGes MG, Inc.(hereinafter called “AnGes MG”) has been co-developing an oral therapeutic vaccine for precancerous condition of cervix with GenoLac BL Corporation (Head office: Naha, Okinawa/President: Tomomitsu Sewaki), BioLeaders Corporation (Head office: Korea/CEO: Sung Moon-Hee) and Dr. Kei Kawana, lecturer at Department of Obstetrics & Gynecology, University of Tokyo (Head of Gynecologic Surgery at the same hospital). AnGes MG is pleased to announce that Morishita Jintan, Co. Ltd. (hereinafter called “Morishita Jintan”) has decided to participate in the joint development group.

HPV (human papillomavirus) is known to be responsible for cervical cancer. The oncoprotein is detected from early stage of precancerous lesion and increases as the precancerous lesion progresses into cervical intraepithelial neoplasia, finally advancing to cervical cancer.

The joint development group including AnGes MG is developing a Lactobacillus casei-derived vaccine to prevent the development of cervical cancer by effectively inducing cellular immunity specific to HVP oncoproteins in cervix using and expects it will be the first-in-class therapeutic vaccine.

It has been reported that patients who have undergone conization of the cervix have increased risks of premature delivery, low birth weight and caesarean section. Thus, it is of great significance to avoid conization of the cervix with our treatment vaccine. Currently, there is no other treatment option available for precancerous lesions; therefore, an early realization of this therapeutic vaccine is desired.

In this development, effective drug delivery system (DDS) is aimed for by encapsulating vaccine with an enteric-coated seamless capsule, so that vaccine remains unaffected by gastric acid after oral intake. This enteric-coated seamless capsule technology has already been applied in such projects as oral vaccine for infection project by Morishita Jintan and Dr. Toshiro Shirakawa, associate professor in Kobe University Graduate School of Medicine and on NF-κB decoy oligo developed by AnGes MG for the treatment of inflammatory bowel disease.

Applying capsule technology by Morishita Jintan to medicines that AnGes MG develops enables to provide the drug products with high additional value. Both companies will make their efforts to make the earliest launch of the therapeutic vaccine possible.

Meanwhile, this trend will have only minor effect on the business performance for the fiscal year of 2012 and there will be no change made on the published value.

###